Page last updated: 2024-08-17

quinidine and midazolam

quinidine has been researched along with midazolam in 40 studies

Research

Studies (40)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (10.00)18.2507
2000's16 (40.00)29.6817
2010's18 (45.00)24.3611
2020's2 (5.00)2.80

Authors

AuthorsStudies
Giacomini, KM; Schaner, ME; Zhang, L1
Topliss, JG; Yoshida, F1
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA1
Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Abraham, MH; Acree, WE; Ibrahim, A1
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W1
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Dai, R; Liu, Y; She, M; Wu, Z1
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ1
Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Dalvie, D; Loi, CM; Smith, DA1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Gunaydin, H; Sun, Y; Weiss, MM1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J1
Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL1
Acevedo, O; Dasararaju, G; Devadasan, V; Halakova, D; Jayaprakash, V; Kovacikova, L; Mohd Siddique, MU; Mondal, SK; Prnova, MS; Shilkar, D; Stefek, M; Thakur, A; Yasmin, S1
Chen, J; Follath, F; Freiburghaus, AU; Ha, HR; Leuenberger, PM1
Bayliss, MK; Eddershaw, PJ; Herriott, D; Manchee, GR; Park, GR; Ranshaw, LE; Tarbit, MH1
Birkett, DJ; Coville, PF; Miners, JO; Walker, RJ; Wanwimolruk, S; Zhang, H1
Bigler, L; Follath, F; Ha, HR; Kozlik, P; Stieger, B1
Galetin, A; Hallifax, D; Houston, JB; Ito, K1
Bhoopathy, S; Karnes, HT; Unger, SE; Xin, B1
Foti, RS; Rock, DA; Wahlstrom, JL; Wienkers, LC1
Baba, K; Hamahata, Y; Hayashi, M; Iwanaga, K; Kakemi, M; Miyazaki, M; Shibano, M; Taniguchi, M1
Agrawal, V; Choi, JH; Giacomini, KM; Miller, WL1
Chen, Y; Subramanian, R; Zhu, X1
Andersson, TB; Bäckström, T; Bertilsson, L; Björkhem-Bergman, L; Bredberg, E; Diczfalusy, U; Nylén, H; Rönquist-Nii, Y1
Ishigai, M; Kato, M; Mitsui, T; Miyake, T; Nagao, S; Nemoto, T; Ogawa, K; Yamada, H1

Reviews

1 review(s) available for quinidine and midazolam

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for quinidine and midazolam

ArticleYear
Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
    Drug metabolism and pharmacokinetics, 2014, Volume: 29, Issue:4

    Topics: Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Hydrocortisone; Hydroxycholesterols; Midazolam; Quinidine; Quinine; Rifampin

2014

Other Studies

38 other study(ies) available for quinidine and midazolam

ArticleYear
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
    The Journal of pharmacology and experimental therapeutics, 1998, Volume: 286, Issue:1

    Topics: Carrier Proteins; Corticosterone; HeLa Cells; Humans; Membrane Proteins; Midazolam; Organic Cation Transporter 1; Permeability; Recombinant Proteins; Structure-Activity Relationship; Tetraethylammonium Compounds; Transfection

1998
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Rational use of in vitro P-glycoprotein assays in drug discovery.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:2

    Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera

2001
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
    Journal of medicinal chemistry, 2003, Apr-24, Volume: 46, Issue:9

    Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine

2003
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
    European journal of medicinal chemistry, 2008, Volume: 43, Issue:3

    Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization

2008
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:4

    Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software

2009
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution

2009
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
    Bioorganic & medicinal chemistry, 2009, Oct-01, Volume: 17, Issue:19

    Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
    Journal of enzyme inhibition and medicinal chemistry, 2011, Volume: 26, Issue:3

    Topics: Cytochrome P-450 Enzyme Inhibitors; Enzyme Activation; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Molecular Structure; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity

2011
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:3

    Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results

2011
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:3

    Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution

2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds.
    ACS medicinal chemistry letters, 2013, Jan-10, Volume: 4, Issue:1

    Topics:

2013
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
    Journal of medicinal chemistry, 2018, 01-11, Volume: 61, Issue:1

    Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water

2018
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
    European journal of medicinal chemistry, 2021, Mar-05, Volume: 213

    Topics: Administration, Oral; Animals; Arthritis; Cells, Cultured; Dimerization; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Development; Enzyme Inhibitors; Freund's Adjuvant; Humans; Lipopolysaccharides; Male; Mice; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type II; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; RAW 264.7 Cells; Structure-Activity Relationship

2021
Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
    European journal of medicinal chemistry, 2021, Nov-05, Volume: 223

    Topics: Aldehyde Reductase; Animals; Caco-2 Cells; Catalytic Domain; Dogs; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Rats, Wistar; Structure-Activity Relationship; Thiazolidinediones

2021
In vitro inhibition of midazolam and quinidine metabolism by flavonoids.
    European journal of clinical pharmacology, 1995, Volume: 48, Issue:5

    Topics: Anti-Arrhythmia Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Flavonoids; Humans; Kinetics; Midazolam; Mixed Function Oxygenases; Quinidine

1995
The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.
    Drug metabolism and disposition: the biological fate of chemicals, 1996, Volume: 24, Issue:5

    Topics: Adrenergic beta-Agonists; Albuterol; Biomarkers; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Disulfiram; Humans; Isoenzymes; Ketoconazole; Microsomes, Liver; Midazolam; Molecular Structure; Oxidation-Reduction; Quinidine; Recombinant Proteins; Salmeterol Xinafoate; Sulfaphenazole; Theophylline

1996
Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.
    British journal of clinical pharmacology, 1997, Volume: 43, Issue:3

    Topics: Antimalarials; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Hydroxylation; Isoenzymes; Kinetics; Male; Microsomes, Liver; Midazolam; Middle Aged; Oxidoreductases, N-Demethylating; Quinidine; Quinine

1997
Metabolism of amiodarone (Part III): identification of rabbit cytochrome P450 isoforms involved in the hydroxylation of mono-N-desethylamiodarone.
    Xenobiotica; the fate of foreign compounds in biological systems, 2001, Volume: 31, Issue:5

    Topics: Amiodarone; Animals; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Aryl Hydrocarbon Hydroxylases; Benzoflavones; Chromatography, High Pressure Liquid; Cimetidine; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ketoconazole; Kinetics; Microsomes, Liver; Midazolam; Models, Chemical; Oxidoreductases, N-Demethylating; Protein Isoforms; Quinidine; Rabbits; Rifampin; Time Factors

2001
CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.
    The Journal of pharmacology and experimental therapeutics, 2005, Volume: 314, Issue:1

    Topics: Algorithms; Anti-Arrhythmia Agents; Area Under Curve; Azoles; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Forecasting; Humans; Hypnotics and Sedatives; In Vitro Techniques; Kinetics; Microsomes; Midazolam; Nifedipine; Quinidine; Substrate Specificity; Testosterone

2005
A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes.
    Journal of pharmaceutical and biomedical analysis, 2005, Apr-01, Volume: 37, Issue:4

    Topics: Algorithms; Animals; Antitussive Agents; Chlorpromazine; Chromatography, Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Enzyme Inhibitors; Half-Life; Humans; Hypnotics and Sedatives; In Vitro Techniques; Indicators and Reagents; Isoenzymes; Microsomes, Liver; Midazolam; Pharmaceutical Preparations; Primaquine; Quinidine; Rats; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization

2005
Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:6

    Topics: Algorithms; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Felodipine; Microsomes, Liver; Midazolam; Molecular Structure; Nifedipine; Quinidine; Substrate Specificity; Testosterone

2010
Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:8

    Topics: Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Furocoumarins; Humans; Medicine, Kampo; Midazolam; Quinidine

2010
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.
    Pharmacogenetics and genomics, 2010, Volume: 20, Issue:10

    Topics: Biocatalysis; Cytochrome P-450 CYP3A; Erythromycin; Genetic Variation; Humans; Kinetics; Midazolam; Mutant Proteins; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Quinidine; Substrate Specificity; Testosterone

2010
Comparison of information-dependent acquisition, SWATH, and MS(All) techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry.
    Analytical chemistry, 2014, Jan-21, Volume: 86, Issue:2

    Topics: Algorithms; Animals; Biotransformation; Chlorpromazine; Chromatography, High Pressure Liquid; Ethanolamines; Microsomes, Liver; Midazolam; Oxidation-Reduction; Quinidine; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2014
A useful model capable of predicting the clearance of cytochrome 3A4 (CYP3A4) substrates in humans: validity of CYP3A4 transgenic mice lacking their own Cyp3a enzymes.
    Drug metabolism and disposition: the biological fate of chemicals, 2014, Volume: 42, Issue:9

    Topics: Alprazolam; Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Felodipine; Humans; Male; Mice; Mice, Transgenic; Microsomes, Liver; Midazolam; Nifedipine; Nitrendipine; Quinidine

2014